Shrujal Baxi
Medical Oncology · New York, NYNPI 1407003742
Payments from drug & device makers
$544,166in general payments, 2019–2025
Across 10 payments — averaging $54,417 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$538K
- E.r. Squibb & Sons, L.L.C.$3K
- Astrazeneca UK Limited$3K
- Varian Medical Systems, Inc.$29
What the payments were for
- Consulting fees$2,70044%
- Travel & lodging$3,30754%
- Food & beverage$1312%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $538,028 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,409 |
| Astrazeneca UK Limited | 1 | $2,700 |
| Varian Medical Systems, Inc. | 1 | $29 |
How this compares
$544,166 in reported general payments places this provider in the 60th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.